Sverre E Kjeldsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8324740/publications.pdf

Version: 2024-02-01

314 papers	57,788 citations	10956 71 h-index	1022 235 g-index
323 all docs	323 docs citations	323 times ranked	34090 citing authors

#	Article	IF	Citations
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
3	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, The, 2002, 359, 995-1003.	6.3	4,917
4	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
5	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.3	4,251
6	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trialâ€"Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, The, 2003, 361, 1149-1158.	6.3	3,420
7	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, The, 2005, 366, 895-906.	6.3	2,662
8	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, The, 2004, 363, 2022-2031.	6.3	2,422
9	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.3	2,129
10	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, The, 2002, 359, 1004-1010.	6.3	1,520
11	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.3	1,236
12	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.3	1,152
13	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. Journal of the American College of Cardiology, 2005, 45, 712-719.	1.2	796
14	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31, 1925-1938.	0.3	789
15	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.3	689
16	Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events. JAMA - Journal of the American Medical Association, 2004, 292, 2343.	3.8	566
17	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, The, 2004, 363, 2049-2051.	6.3	540
18	Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Hypertension, 2005, 45, 198-202.	1.3	529

#	Article	IF	Citations
19	Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. Annals of Internal Medicine, 2003, 139, 901.	2.0	468
20	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International, 2004, 65, 1041-1049.	2.6	410
21	Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. JAMA - Journal of the American Medical Association, 2002, 288, 1491.	3.8	389
22	Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. Journal of the American College of Cardiology, 2010, 55, 2299-2307.	1.2	374
23	Hypertension and cardiovascular risk: General aspects. Pharmacological Research, 2018, 129, 95-99.	3.1	365
24	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	0.7	355
25	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension, 2002, 20, 1879-1886.	0.3	345
26	Characteristics of 9194 Patients With Left Ventricular Hypertrophy. Hypertension, 1998, 32, 989-997.	1.3	272
27	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	0.7	254
28	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. Journal of the American College of Cardiology, 2005, 45, 705-711.	1.2	250
29	Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol. Circulation, 2003, 108, 684-690.	1.6	241
30	Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension. JAMA - Journal of the American Medical Association, 2006, 296, 1242.	3.8	238
31	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
32	ESH Position Paper. Journal of Hypertension, 2012, 30, 837-841.	0.3	227
33	Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death. Circulation, 2007, 116, 700-705.	1.6	203
34	Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial. Hypertension, 2016, 67, 808-812.	1.3	193
35	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of Hypertension, 2008, 26, 403-411.	0.3	190
36	Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-Resistant Hypertension. Hypertension, 2014, 63, 991-999.	1.3	179

#	Article	IF	Citations
37	Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252.	0.3	177
38	Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension. American Journal of Cardiology, 2012, 109, 685-692.	0.7	157
39	Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. European Heart Journal, 2018, 39, 2243-2251.	1.0	156
40	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	1.3	147
41	Exercise Blood Pressure Predicts Mortality From Myocardial Infarction. Hypertension, 1996, 27, 324-329.	1.3	140
42	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension, 2006, 24, 1405-1412.	0.3	139
43	Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men. Hypertension, 2012, 59, 198-204.	1.3	139
44	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. Journal of Hypertension, 2006, 24, 2163-2168.	0.3	138
45	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial. Hypertension, 2006, 48, 385-391.	1.3	138
46	Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension, 2001, 19, 1149-1159.	0.3	135
47	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	1.2	124
48	Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, 43, 1047-1055.	1.2	119
49	The global burden of hypertension exceeds 1.4 billion people. Journal of Hypertension, 2019, 37, 1148-1153.	0.3	116
50	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. Journal of Hypertension, 2004, 22, 1805-1811.	0.3	114
51	Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension, 2021, 77, 692-705.	1.3	112
52	Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients. Annals of Internal Medicine, 2007, 147, 311.	2.0	106
53	Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention Trials. Blood Pressure, 2001, 10, 190-192.	0.7	104
54	Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Journal of Hypertension, 2000, 18, 629-642.	0.3	103

#	Article	IF	Citations
55	Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure. Hypertension, 2013, 62, 526-532.	1.3	103
56	Electrocardiographic Strain Pattern and Prediction of New-Onset Congestive Heart Failure in Hypertensive Patients. Circulation, 2006, 113, 67-73.	1.6	102
57	Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients. Hypertension, 2000, 36, 766-773.	1.3	100
58	Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population. Hypertension, 2007, 50, 467-473.	1.3	99
59	VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. American Journal of Hypertension, 2003, 16, 544-548.	1.0	97
60	Updated National and International Hypertension Guidelines: A Review of Current Recommendations. Drugs, 2014, 74, 2033-2051.	4.9	95
61	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. European Heart Journal, 2016, 37, 955-964.	1.0	95
62	Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol. Hypertension, 2005, 45, 46-52.	1.3	90
63	Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. Journal of Hypertension, 2001, 19, 1343-1348.	0.3	84
64	All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. European Heart Journal, 2010, 31, 2271-2279.	1.0	84
65	Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. Journal of Hypertension, 2008, 26, 2064-2070.	0.3	82
66	Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial. Blood Pressure, 2001, 10, 83-91.	0.7	80
67	Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study. Journal of Hypertension, 2006, 24, 775-781.	0.3	80
68	The Effect of Angiotensin II Receptor Blockade on Insulin Sensitivity and Sympathetic Nervous System Activity in Primary Hypertension. Blood Pressure, 1994, 3, 185-188.	0.7	75
69	Hypertension Optimal Treatment (HOT) Study. Hypertension, 1998, 31, 1014-1020.	1.3	72
70	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	0.7	65
71	Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. American Heart Journal, 2004, 148, 747-754.	1.2	64
72	Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension, 2015, 66, 368-373.	1.3	63

#	Article	IF	Citations
73	Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment. Circulation, 2009, 119, 1883-1891.	1.6	61
74	Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 243-251.	2.1	61
75	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
76	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	1.3	61
77	Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention, 2013, 9, R58-R66.	1.4	60
78	Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy. Hypertension, 2012, 60, 347-353.	1.3	59
79	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Pressure, 2016, 25, 83-92.	0.7	59
80	Relationship Between Insulin Sensitivity and Maximal Forearm Blood Flow in Young Men. Hypertension, 1998, 32, 838-843.	1.3	56
81	Low Heart Rates Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 726-731.	2.1	56
82	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	5.1	56
83	Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 337-343.	2.1	54
84	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. Journal of Hypertension, 2005, 23, 891-898.	0.3	53
85	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. Journal of Hypertension, 2009, 27, 673-679.	0.3	53
86	Fixed-Dose Combinations in the Management of Hypertension. American Journal of Cardiovascular Drugs, 2005, 5, 17-22.	1.0	50
87	Is smoking a causative factor of hypertension?. Blood Pressure, 2005, 14, 69-71.	0.7	49
88	Impact of lower achieved blood pressure on outcomes in hypertensive patients. Journal of Hypertension, 2012, 30, 802-810.	0.3	49
89	Whole Blood Viscosity, Blood Pressure and Cardiovascular Risk Factors in Healthy Blood Donors. Blood Pressure, 1997, 6, 161-165.	0.7	48
90	Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Pressure, 2018, 27, 247-248.	0.7	47

#	Article	IF	Citations
91	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
92	Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension*. American Journal of Hypertension, 1995, 8, 704-711.	1.0	45
93	Home Blood Pressure Monitoring. Current Knowledge and Directions for Future Research. Blood Pressure, 2001, 10, 271-287.	0.7	44
94	Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy. Circulation, 2005, 111, 1924-1931.	1.6	43
95	Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. Journal of Hypertension, 2007, 25, 15-23.	0.3	43
96	1999 WHO/ISH Hypertension guidelines - highlights & ESH update. Journal of Hypertension, 2002, 20, 153-155.	0.3	42
97	Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	40
98	Insulin Sensitivity Is Related to Physical Fitness and Exercise Blood Pressure to Structural Vascular Properties in Young Men. Hypertension, 1999, 33, 781-786.	1.3	39
99	Predictors of 7-year changes in exercise blood pressure. Journal of Hypertension, 1997, 15, 245-249.	0.3	38
100	Clustering of coronary risk factors with increasing blood pressure at rest and during exercise. Journal of Hypertension, 1998, 16, 19-22.	0.3	38
101	Hyperresponders vs. nonresponder patients after renal denervation. Journal of Hypertension, 2014, 32, 2422-2427.	0.3	37
102	Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy. Hypertension, 2005, 45, 580-585.	1.3	35
103	The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120â€‰mmHg. Blood Pressure, 2016, 25, 1-3.	0.7	35
104	The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study. Journal of Clinical Hypertension, 2005, 7, 152-158.	1.0	34
105	Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovascular Diabetology, 2009, 8, 51.	2.7	33
106	Physician (investigator) inertia in apparent treatment-resistant hypertension â€“ Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Pressure, 2015, 24, 1-6.	0.7	33
107	Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. Journal of Hypertension, 2002, 20, 1231-1237.	0.3	32
108	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports, 2016, 18, 6.	1.5	32

#	Article	IF	Citations
109	The role of beta-blockers in the treatment of chronic heart failure. Trends in Pharmacological Sciences, 2011, 32, 206-212.	4.0	31
110	The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140â€‰mmHg rather than below 120â€‰mmHg. Blood Pressure, 2016, 25, 63-66.	0.7	31
111	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure, 2017, 26, 195-203.	0.7	31
112	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Blood Pressure, 2020, 29, 135-136.	0.7	31
113	Change in Cardiorespiratory Fitness and Risk of Stroke and Death. Stroke, 2019, 50, 155-161.	1.0	30
114	Renal Denervation after Symplicity HTN-3: An Update. Current Hypertension Reports, 2014, 16, 460.	1.5	29
115	Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Pressure, 2016, 25, 333-336.	0.7	29
116	Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men. European Journal of Preventive Cardiology, 2018, 25, 1655-1663.	0.8	29
117	Patients with treatment-resistant hypertension report increased stress and anxiety. Journal of Hypertension, 2013, 31, 610-615.	0.3	28
118	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension, 2021, 78, 555-558.	1.3	28
119	Effects of Increased Arterial Epinephrine on Insulin, Glucose and Phosphate. Blood Pressure, 1996, 5, 27-31.	0.7	27
120	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. Hypertension, 2015, 65, 5-15.	1.3	27
121	Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 79-80.	1.4	27
122	Are fixed-dose combination antihypertensives suitable as first-line therapy?. Current Medical Research and Opinion, 2012, 28, 1685-1697.	0.9	26
123	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. Journal of Hypertension, 2008, 26, 1244-1249.	0.3	25
124	Cardiovascular outcomes in hypertensive patients. Journal of Hypertension, 2012, 30, 2213-2222.	0.3	25
125	Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men. Hypertension, 2020, 75, 44-50.	1.3	25
126	Sympathetic Nervous System Involvement in Essential Hypertension: Increased Platelet Noradrenaline Coincides with Decreased Î²-Adrenoreceptor Responsiveness. Blood Pressure, 1994, 3, 164-171.	0.7	24

#	Article	IF	Citations
127	Plasma catecholamines, blood pressure responses and perceived stress during mental arithmetic stress in young men. Blood Pressure, 2004, 13, 287-294.	0.7	24
128	High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. Blood Pressure, 2004, 13, 89-94.	0.7	24
129	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. Journal of Hypertension, 2020, 38, 1396-1406.	0.3	23
130	Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Current Medical Research and Opinion, 2007, 23, 259-270.	0.9	21
131	Effect of Changing Heart Rate During Treatment of Hypertension on Incidence of Heart Failure. American Journal of Cardiology, 2012, 109, 699-704.	0.7	20
132	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure, 2017, 26, 321-331.	0.7	20
133	Adopting Systolic Pressure Intervention Trial (SPRINT)-like office blood pressure measurements in clinical practice. Journal of Hypertension, 2017, 35, 471-472.	0.3	20
134	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.3	20
135	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension, 2022, 79, 1153-1166.	1.3	20
136	Evaluation of Self-Measured Home vs. Clinic Intra-Arterial Blood Pressure. Blood Pressure, 1993, 2, 28-34.	0.7	19
137	Interaction between inflammation and blood viscosity predicts cardiovascular mortality. Scandinavian Cardiovascular Journal, 2010, 44, 107-112.	0.4	19
138	The Un-Observed Automated Office Blood Pressure Measurement Technique Used in the SPRINT Study Points to a Standard Target Office Systolic Blood Pressure <140ÂmmHg. Current Hypertension Reports, 2017, 19, 3.	1.5	19
139	Losartan benefits over atenolol in nonâ€smoking hypertensive patients with left ventricular hypertrophy: The LIFE study. Blood Pressure, 2004, 13, 376-384.	0.7	18
140	Mechanism of Angiotensin II Type 1 Receptor Blocker Action in the Regression of Left Ventricular Hypertrophy. Journal of Clinical Hypertension, 2006, 8, 487-492.	1.0	18
141	Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. Journal of Hypertension, 2009, 27, 2271-2277.	0.3	17
142	Serial assessment of the electrocardiographic strain pattern for prediction of newâ€onset heart failure during antihypertensive treatment: the LIFE study. European Journal of Heart Failure, 2011, 13, 384-391.	2.9	17
143	Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men. Blood Pressure, 2017, 26, 229-236.	0.7	17
144	Relationship between abnormal P-wave terminal force in lead V₁ and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study. Blood Pressure, 2017, 26, 94-101.	0.7	17

#	Article	IF	Citations
145	Diuretics in the LIFE study. Lancet, The, 2004, 364, 413-414.	6.3	16
146	Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure, 2009, 18, 348-361.	0.7	16
147	A Case for Less Intensive Blood Pressure Control: It Matters to Achieve Target Blood Pressure Early and Sustained Below 140/90mmHg. Progress in Cardiovascular Diseases, 2016, 59, 209-218.	1.6	16
148	New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Pressure, 2018, 27, 62-65.	0.7	16
149	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Pressure, 2021, 30, 1-3.	0.7	16
150	Seven-Year Increase in Exercise Systolic Blood Pressure at Moderate Workload Predicts Long-Term Risk of Coronary Heart Disease and Mortality in Healthy Middle-Aged Men. Hypertension, 2013, 61, 1134-1140.	1.3	15
151	Heart Rate as a Predictor of Stroke in High-risk, Hypertensive Patients with Previous Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2814-2818.	0.7	15
152	Cardiac Conduction with Diltiazem and Beta-Blockade Combined. A Review and Report on Cases. Blood Pressure, 1996, 5, 260-263.	0.7	14
153	Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment. Blood Pressure, 2014, 23, 71-80.	0.7	14
154	Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile. Journal of Hypertension, 2014, 32, 2488-2498.	0.3	14
155	Clinical Implications of the 2013 ESH/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring. Drugs in R and D, 2014, 14, 31-43.	1.1	14
156	Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study. European Journal of Preventive Cardiology, 2016, 23, 59-66.	0.8	14
157	The Global Burden of Disease Study 2015 and Blood Pressure. Blood Pressure, 2017, 26, 1-1.	0.7	14
158	2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Blood Pressure, 2018, 27, 313-313.	0.7	14
159	Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. Journal of Hypertension, 2020, 38, 2144-2145.	0.3	14
160	Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk. European Journal of Preventive Cardiology, 2013, 20, 541-548.	0.8	13
161	Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy MiddleâEAged Men: a 28â€Year FollowâEUp Study. Journal of the American Heart Association, 2016, 5, .	1.6	13
162	From â€˜essentialâ€™ hypertension to intensive blood pressure lowering: the pros and cons of lower target values. European Heart Journal, 2017, 38, 3258-3271.	1.0	13

#	Article	IF	Citations
163	INSIGHT and NORDIL. Lancet, The, 2000, 356, 1929-1930.	6.3	12
164	Serum Uric Acid and Hemorheology in Borderline Hypertensives and in Subjects with Established Hypertension and Left Ventricular Hypertrophy. Blood Pressure, 2003, 12, 104-110.	0.7	12
165	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure, 2008, 17, 170-177.	0.7	12
166	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. Frontiers in Physiology, 2015, 6, 9.	1.3	12
167	Systolic Blood Pressure Control and Mortality After Stroke in Hypertensive Patients. Stroke, 2015, 46, 2113-2118.	1.0	12
168	Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. Clinical Drug Investigation, 2016, 36, 225-233.	1.1	12
169	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.3	12
170	Optimal Blood Pressure Target in Diabetic and Nondiabetic Hypertensive Patients. Circulation Research, 2018, 123, 528-530.	2.0	12
171	Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk. Journal of Hypertension, 2019, 37, 6-8.	0.3	12
172	Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men. Stroke, 2020, 51, 1435-1441.	1.0	12
173	2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines. Blood Pressure, 2013, 22, 191-192.	0.7	11
174	Renal denervation in treatment-resistant hypertension: a reappraisal. Current Opinion in Pharmacology, 2015, 21, 48-52.	1.7	11
175	Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes. European Journal of Internal Medicine, 2016, 29, 26-31.	1.0	11
176	Long-term predictors of stroke in healthy middle-aged men. International Journal of Stroke, 2018, 13, 292-300.	2.9	11
177	Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Pressure, 2019, 28, 317-326.	0.7	11
178	Blood Pressureâ€“Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. Hypertension, 2020, 75, 1584-1592.	1.3	11
179	Effects of Î²1- and Î²2-blockade on blood pressure and sympathetic responses to flight phobia stress. Clinical Pharmacology and Therapeutics, 1990, 47, 599-607.	2.3	10
180	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Pressure, 2008, 17, 260-269.	0.7	10

#	Article	IF	Citations
181	Treatment of hypertension in diabetes: what is the best therapeutic option?. Expert Review of Cardiovascular Therapy, 2012, 10, 727-734.	0.6	10
182	First-in-Man Randomized Clinical Trial of Renal Denervation for Atrial Arrhythmia Raises Concern. Journal of the American College of Cardiology, 2013, 62, e445-e446.	1.2	10
183	High screening blood pressure at young age predicts future masked hypertension: A 17 year follow-up study. Blood Pressure, 2015, 24, 131-138.	0.7	10
184	Take a blood pressure pill or undergo renal denervation?. Lancet, The, 2018, 391, 2298-2300.	6.3	10
185	Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study. Blood Pressure, 2021, 30, 51-59.	0.7	10
186	Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations. Hypertension, 2021, 78, 617-628.	1.3	10
187	Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor. Clinical Pharmacology and Therapeutics, 1990, 48, 41-49.	2.3	9
188	Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 227-234.	1.0	9
189	The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. Blood Pressure, 2017, 26, 131-132.	0.7	9
190	New data on antihypertensive drugs and risk of cancer: should we worry?. Blood Pressure, 2019, 28, 1-3.	0.7	9
191	Polymorphisms in Candidate Genes for Blood Pressure Regulation in Young Men with Normal or Elevated Screening Blood Pressure. Blood Pressure, 2001, 10, 92-100.	0.7	8
192	Targeting the reninâ€“angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opinion on Emerging Drugs, 2005, 10, 729-745.	1.0	8
193	The J-curve phenomenon revisited. Blood Pressure, 2009, 18, 168-170.	0.7	8
194	Cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension and improving patientsâ€™ adherence. Journal of Hypertension, 2014, 32, 2357-2358.	0.3	8
195	Blood pressure and early neurological deterioration in acute ischemic stroke. Journal of Hypertension, 2015, 33, 2020-2021.	0.3	8
196	Arterial Stiffness Predicts Incident Atrial Fibrillation in the Framingham Heart Study. Hypertension, 2016, 68, 555-557.	1.3	8
197	Letter by Messerli et al Regarding Article, â€œThe Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressureâ€• Circulation, 2017, 135, e45-e46.	1.6	8
198	Catheter-based renal denervation: a word of caution. EuroIntervention, 2013, 8, 997-998.	1.4	8

#	Article	IF	Citations
199	Never mind the quality, feel the width â€“ ALLHAT revisited. Blood Pressure, 2004, 13, 330-334.	0.7	7
200	Valsartan in the treatment of hypertension. Aging Health, 2005, 1, 27-36.	0.3	7
201	Angiotensin receptor - neprilysin inhibiton (ARNI) â€“ A novel therapeutic concept for management of hypertension and heart failure. Blood Pressure, 2012, 21, 329-330.	0.7	7
202	Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3. Blood Pressure, 2013, 22, 279-281.	0.7	7
203	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 48-56.	1.4	7
204	Future of Renal Sympathetic Denervation in the Treatment of Hypertension. Journal of the American College of Cardiology, 2019, 73, 1643-1645.	1.2	7
205	Cuff-less measurements of blood pressure: are we ready for a change?. Blood Pressure, 2021, 30, 205-207.	0.7	7
206	Editorial: Arterial Plasma Adrenaline in Essential Hypertension. Scandinavian Journal of Clinical and Laboratory Investigation, 1984, 44, 271-274.	0.6	6
207	Comparison of Home and Office Blood Pressure in Treated Hypertensives in the Nordic Diltiazem (NORDIL) Study. Blood Pressure, 2002, 11, 371-376.	0.7	6
208	Hypertension treatment and stroke prevention. Blood Pressure, 2003, 12, 264-268.	0.7	6
209	Telmisartan/Hydrochlorothiazide Combination Therapy for the Treatment of Hypertension: A Pooled Analysis in Older and Younger Patients. Journal of Clinical Hypertension, 2013, 15, 380-388.	1.0	6
210	Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Pressure, 2014, 23, 256-261.	0.7	6
211	Renal denervation in treatment-resistant hypertension â€“ Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials. Blood Pressure, 2014, 23, 135-137.	0.7	6
212	Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy. American Journal of Hypertension, 2014, 27, 966-972.	1.0	6
213	Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions. Blood Pressure, 2018, 27, 1-2.	0.7	6
214	SBP above 180â€ŠmmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up. Journal of Hypertension, 2019, 37, 949-955.	0.3	6
215	Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: Life, scope, and value. Current Hypertension Reports, 2005, 7, 155-157.	1.5	5
216	Are All the Hypertensives Made Equal?. Herz, 2006, 31, 323-330.	0.4	5

#	Article	IF	Citations
217	Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. Current Medical Research and Opinion, 2010, 26, 879-887.	0.9	5
218	No Support for Renal Denervation in a Meta-Analysis. Journal of the American College of Cardiology, 2013, 62, 2029-2030.	1.2	5
219	Design of renal denervation studies not confounded by antihypertensive drugs. Journal of the American Society of Hypertension, 2015, 9, 337-340.	2.3	5
220	The Setback of Renal Denervation Should Not Backfire onÂSympathetic Overactivity in Hypertension âˆ—. Journal of the American College of Cardiology, 2015, 65, 1322-1323.	1.2	5
221	HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140â€‰mmHg. Blood Pressure, 2016, 25, 131-132.	0.7	5
222	Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. Blood Pressure, 2018, 27, 185-187.	0.7	5
223	Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. Blood Pressure, 2019, 28, 356-357.	0.7	5
224	Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?. Blood Pressure, 2019, 28, 75-76.	0.7	5
225	Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. Journal of Hypertension, 2011, 29, 997-1004.	0.3	4
226	Renal nerve ablation: Emerging role in therapeutics. Blood Pressure, 2011, 20, 253-255.	0.7	4
227	High resting heart rate predicts mortality, disability, and cognitive decline in patients after ischaemic stroke: time for additional selective I(f) channel inhibitor trials?. European Heart Journal, 2012, 33, 2761-2763.	1.0	4
228	Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. Journal of Clinical Hypertension, 2015, 17, 141-146.	1.0	4
229	Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy. Blood Pressure, 2016, 25, 364-372.	0.7	4
230	Blood pressure goals in type 2 diabetesâ€”assessing the evidence. Lancet Diabetes and Endocrinology,the, 2017, 5, 319-321.	5.5	4
231	Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?. Blood Pressure, 2017, 26, 193-194.	0.7	4
232	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	1.3	4
233	Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 151-158.	1.0	4
234	The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure. Journal of Hypertension, 2018, 36, 916-923.	0.3	4

#	Article	IF	Citations
235	Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mmâ€‰Hg in Patients With Diabetes Mellitus Participating in ACCORD?. Hypertension, 2018, 72, 291-293.	1.3	4
236	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure, 2021, 30, 90-97.	0.7	4
237	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure, 2021, 30, 82-89.	0.7	4
238	Directly Observed Therapy in Hypertension (DOT-HTN). Updates in Hypertension and Cardiovascular Protection, 2018, , 57-85.	0.1	4
239	Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects. EuroIntervention, 2013, 9, R7-R9.	1.4	4
240	The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. Blood Pressure, 2021, 30, 327-331.	0.7	4
241	Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vascular Health and Risk Management, 2007, 3, 299-305.	1.0	4
242	The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease. Blood Pressure, 2016, 25, 276-279.	0.7	3
243	Are People With Masked Hypertension Adherent to Their Antihypertensive Medication?. Hypertension, 2019, 74, 497-498.	1.3	3
244	The PARAGON Heart Failure trial â€“ ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 215-216.	0.7	3
245	Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure. Journal of Hypertension, 2021, 39, 2022-2029.	0.3	3
246	Hypertension management during the COVID-19 pandemic: what can we learn for the future?. Blood Pressure, 2022, 31, 47-49.	0.7	3
247	Serum Uric Acid and Hemorheology in Borderline Hypertensives and in Subjects with Established Hypertension and Left Ventricular Hypertrophy. Blood Pressure, 2003, 12, 104-110.	0.7	3
248	Insulin Resistance and Sympathetic Nervous System Activity in Hypertensive and Normotensive Premenopausal Women. Blood Pressure, 1995, 4, 287-292.	0.7	2
249	Relation of serum uric acid to cardiovascular endpoints in hypertension: the life study. American Journal of Hypertension, 2003, 16, A9.	1.0	2
250	Hypertension and atrial fibrillation with emphasis on prevention. Blood Pressure, 2009, 18, 94-98.	0.7	2
251	An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Review of Cardiovascular Therapy, 2013, 11, 673-682.	0.6	2
252	Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. Journal of Clinical Pharmacology, 2016, 56, 1120-1129.	1.0	2

#	Article	IF	Citations
253	Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials. Journal of Hypertension, 2016, 34, 1489-1491.	0.3	2
254	Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Blood Pressure, 2016, 25, 235-240.	0.7	2
255	The INTERSALT Study and the complex relationship between salt intake and blood pressure. Blood Pressure, 2017, 26, 65-66.	0.7	2
256	Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?. Blood Pressure, 2017, 26, 319-320.	0.7	2
257	Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials. Blood Pressure, 2017, 26, 257-258.	0.7	2
258	Take a Blood Pressure Pill or Benefit from Renal Denervation?. European Heart Journal, 2018, 39, 3010-3012.	1.0	2
259	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 122-123.	1.4	2
260	Poor reproducibility of masked and white coat uncontrolled hypertension: important new information on MUCH and WUCH. European Heart Journal, 2020, 41, 1572-1574.	1.0	2
261	Assessing hypertension therapies: randomization or confounding by indication?. Nature Reviews Cardiology, 2020, 17, 73-74.	6.1	2
262	The International Society of Hypertension Guidelines 2020 â€“ a new drug treatment recommendation in the wrong direction?. Blood Pressure, 2020, 29, 264-266.	0.7	2
263	Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?. Blood Pressure, 2020, 29, 341-343.	0.7	2
264	On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Blood Pressure, 2020, 29, 319-326.	0.7	2
265	Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Journal of Hypertension, 2020, Publish Ahead of Print, .	0.3	2
266	Renal Denervation After Symplicity HTN-3 â€“ Back to Basics. Review of the Evidence. European Cardiology Review, 2014, 9, 110.	0.7	2
267	Attended vs. unattended blood pressure â€“ learnings beyond SPRINT. Blood Pressure, 2021, 30, 1-3.	0.7	2
268	Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. Exploration of Medicine, 0, , 128-138.	1.5	2
269	Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophyâ€“Application of A New Multivariate Predictive Model. The Life Study. Reviews in Cardiovascular Medicine, 2022, 23, 095.	0.5	2
270	Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 139-148.	1.5	2

#	Article	IF	Citations
271	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 160-172.	1.5	2
272	Long-Term Pacing in VVI-Modes Elicit Similar Sympathetic Drive. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1114-1115.	0.5	1
273	ESH statement on detection and punishment of abstract fraud and poster plagiarism. Blood Pressure, 2005, 14, 322-323.	0.7	1
274	ESH statement on detection and punishment of abstract fraud and poster plagiarism. Journal of Hypertension, 2006, 24, 203-204.	0.3	1
275	Authors' reply to the letter from Dr Wang: Troponins after coronary artery bypass grafting: Continuous or cut-point approach?. American Heart Journal, 2013, 166, e3.	1.2	1
276	Wolfgang Kiowski. Hypertension, 2013, 61, 268-269.	1.3	1
277	Hypertension Management by Practice Guidelines. Blood Pressure, 2014, 23, 1-2.	0.7	1
278	Long-term survival in the randomized trial of drug treatment in mild to moderate hypertension of the Oslo study 1972â€“3. European Journal of Internal Medicine, 2015, 26, 123-126.	1.0	1
279	Impact of achieved systolic blood pressure on renal function in hypertensive patients. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 271-276.	1.8	1
280	Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients. Journal of Hypertension, 2019, 37, 629-635.	0.3	1
281	Eivind Berge, MD, PhD, 1964â€“2020. Stroke, 2020, 51, 1353-1355.	1.0	1
282	Why we do not need a single independent international hypertension clinical practice guideline. Journal of Hypertension, 2021, 39, 2125-2127.	0.3	1
283	Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of Medicine, 0, , 149-159.	1.5	1
284	Does losartan treated patients with albuminuria have better cardiovascular outcome than those treated with atenolol? The LIFE study. American Journal of Hypertension, 2002, 15, A21.	1.0	0
285	Losartan. American Journal of Cardiovascular Drugs, 2003, 3, 378-379.	1.0	0
286	The effect of baseline physical activity on cardiovascular outcomes in patients treated for hypertension with LVH.. American Journal of Hypertension, 2004, 17, S106.	1.0	0
287	The effect of losartan versus atenolol on carotid atherosclerosis in the common carotid arteries in hypertension. Icarus, a life substudy. American Journal of Hypertension, 2004, 17, S111.	1.0	0
288	Combination treatment in hypertension â€“ the latest 2013 European Guidelines. Blood Pressure, 2013, 22, 1-2.	0.7	0

#	Article	IF	Citations
289	Primary cardiovascular prevention by Mediterranean diet â€“ The PREDIMED trial. Blood Pressure, 2013, 22, 129-130.	0.7	0
290	Response to Letter by Morris et al Regarding Article, â€œLow Heart Rates Predict Incident Atrial Fibrillation in Healthy Middle-Aged Menâ€•by Grundvold et al. Circulation: Arrhythmia and Electrophysiology, 2013, 6, e102.	2.1	0
291	Revisiting the pre-hypertension debate: Increasing evidence for treatment â€“ or not?. Blood Pressure, 2013, 22, 344-344.	0.7	0
292	Telmisartan in combination with hydrochlorothiazide 12.5â€‰mg for the management of patients with hypertension. Current Medical Research and Opinion, 2014, 30, 1715-1724.	0.9	0
293	High blood pressure in US diabetic veterans with normal renal function. Journal of Hypertension, 2016, 34, 836-837.	0.3	0
294	When should we treat hypertension in patients with diabetes?. Nature Reviews Cardiology, 2016, 13, 252-253.	6.1	0
295	Blood Pressure in 2016: increased impact factor and change of editors. Blood Pressure, 2016, 25, 331-332.	0.7	0
296	Prevention and Treatment of Atrial Fibrillation in Patients with Hypertension. , 2016, , 121-136.		0
297	Peter Meredith. Blood Pressure, 2016, 25, 129-130.	0.7	0
298	Interventions to improve adherence of antihypertensive medication in African-Americans. Journal of Hypertension, 2017, 35, 1164-1165.	0.3	0
299	Consensus document on hypertension and cardiac arrhythmias. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 251-252.	1.4	0
300	Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues. European Heart Journal, 2018, 39, 4221-4221.	1.0	0
301	Final Farewell to Alberto Zanchetti MD. European Heart Journal, 2018, 39, 2616-2617.	1.0	0
302	The PARAGON-Heart failure trial â€“ another disappointment for heart failure patients with hypertension and preserved ejection fraction. Blood Pressure, 2019, 28, 276-278.	0.7	0
303	Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. Blood Pressure, 2019, 28, 84-92.	0.7	0
304	Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. Blood Pressure, 2019, 28, 144-145.	0.7	0
305	Could adverse events offset the benefit of intensive blood pressure lowering treatment in the Systolic Blood Pressure Intervention Trial?. Journal of Hypertension, 2019, 37, 902-904.	0.3	0
306	The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. Blood Pressure, 2020, 29, 1-2.	0.7	0

#	Article	IF	Citations
307	Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?. Blood Pressure, 2020, 29, 199-201.	0.7	0
308	How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. Blood Pressure, 2020, 29, 68-69.	0.7	0
309	Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes â€“ from single pill combinations to monitoring of a nationwide health insurance database. Blood Pressure, 2021, 30, 1-2.	0.7	0
310	Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure, 2021, 30, 267-268.	0.7	0
311	The Oslo Ischaemia Study: cohort profile. BMJ Open, 2021, 11, e049111.	0.8	0
312	Losartan vs Atenolol in Prevention of Stroke and Cardiovascular Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2003, 289, 701.	3.8	0
313	A 30th anniversary and a glimpse of the future. Blood Pressure, 2022, 31, 1-3.	0.7	0
314	Thirty years with LIFEâ€”a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0